Literature DB >> 21270787

Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections.

O A Cornely, A J Ullmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21270787     DOI： 10.1038/clpt.2010.261

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  17 in total

1.  Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis.

Authors:  P Campoli; Q Al Abdallah; R Robitaille; N V Solis; J A Fielhaber; A S Kristof; M Laverdiere; S G Filler; D C Sheppard
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.

Authors:  Frank P Tverdek; Sang Taek Heo; Samuel L Aitken; Bruno Granwehr; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

3.  Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  R Greco; M C Barbanti; M T Lupo Stranghellini; F Giglio; M Morelli; C Messina; A Forcina; C Oltolini; S Piemontese; P Scarpellini; S Marktel; A Assanelli; M Carrabba; L Vago; C Corti; M Bernardi; J Peccatori; F Ciceri
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

Review 4.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

5.  Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.

Authors:  Anastasia Wasylyshyn; Kathleen A Linder; Caroline G Castillo; Shiwei Zhou; Carol A Kauffman; Marisa H Miceli
Journal:  Mycopathologia       Date:  2020-01-14       Impact factor: 2.574

6.  Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.

Authors:  Oliver A Cornely; David Helfgott; Amelia Langston; Werner Heinz; Jörg-Janne Vehreschild; Maria J G T Vehreschild; Gopal Krishna; Lei Ma; Susan Huyck; Michael C McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

7.  Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Authors:  Rafael F Duarte; Javier López-Jiménez; Oliver A Cornely; Michel Laverdiere; David Helfgott; Shariq Haider; Pranatharthi Chandrasekar; Amelia Langston; John Perfect; Lei Ma; Marlou L P S van Iersel; Nancy Connelly; Nicholas Kartsonis; Hetty Waskin
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

8.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

9.  Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

Authors:  Johan Maertens; Oliver A Cornely; Andrew J Ullmann; Werner J Heinz; Gopal Krishna; Hernando Patino; Maria Caceres; Nicholas Kartsonis; Hetty Waskin; Michael N Robertson
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

10.  Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.

Authors:  Michael J Dolton; Roger J M Brüggemann; David M Burger; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.